Jump to content

Want to participate in a drug study?

Recommended Posts

  • Chief Cushie




Breaking ground in Cushing's research with...




An Open Label Study of the Efficacy and Safety of CORLUX (mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome"


The SEISMIC Study is a US based clinical research trial designed to test mifepristone in the treatment of the clinical manifestations of endogenous Cushing's Syndrome over a 6 month period of treatment


Patients: Take the questionnaire


SEISMIC Study- Main Inclusion Criteria


Subjects must:



Be at least 18 years of age


Have a confirmed diagnosis of endogenous hypercortisolemia caused by ACTH dependent or ACTH independent etiologies, including:


a. Cushing's Disease that



i. recurred after primary pituitary surgery or



ii. has persisted despite pituitary surgery (failed pituitary surgery) or



iii. has been treated with radiation therapy to the pituitary



iv. is not treatable with surgery



v. exists in patients who are not candidates for surgery


b. Ectopic ACTH


c. Ectopic CRF secretion


d. Adrenal adenoma


e. Adrenal carcinoma


f. Adrenal autonomy


Require medical treatment of hypercortisolemia


Have diabetes mellitus type 2 or glucose intolerance AND/OR have hypertension caused by, or aggravated by hypercortisolemia


Have two or more of the following signs or symptoms related to hypercortisolemia:


? Cushinoid appearance


? Increased body weight or central obesity


? Proximal muscle weakness


? Low bone mass (DXA T < -1.0)


? Psychiatric symptoms (including depression or psychosis)


? Hirsutism and/or violaceous striae and/or acne



SEISMIC Study- Main Exclusion Criteria

Subjects must not:


Have de novo Cushing's disease or be surgical candidates for pituitary surgery


Have an acute or unstable medical problem, which could be aggravated by mifepristone treatment


Be currently taking medications known to significantly induce or inhibit CYP3A4, or have taken these medications within 7 days of Screening


Be pregnant or unable or unwilling to use medically acceptable, non-hormonal methods of contraception during the study (female patients of reproductive potential)


Have received investigational treatment (drug, biological agent or device) within 30 days of Screening


Have a history of an allergic reaction or intolerance to CORLUX (mifepristone)


Have a non-endogenous source of hypercortisolemia such as factious hypercortisolemia (exogenous source of glucocorticoid, iatrogenic Cushing's syndrome), factious or therapeutic use of ACTH


Have Pseudo-Cushing's Syndrome


Receive PPARg agonist drugs (e.g. pioglitazone, rosiglitazone) within 4 months of screening


Have renal failure as defined by a serum creatinine of ?2.2 mg/dL


Be a postmenopausal woman with an intact uterus who has experienced unexplained vaginal bleeding within 12 months of Screening



For more information about the SEISMIC Study, please email us at info@cushingsstudy.com or call 1 877-367-6550



Mifepristone is under investigation for Cushing's Syndrome. It has not been approved by the US FDA for treatment of Cushing's Syndrome.

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...